摘要
目的:调查某院门诊传染病药房抗病毒性肝炎药的临床应用情况并作出客观评估。方法:统计该院门诊传染病药房2007-2010年抗病毒性肝炎药的销售金额、主要品种、用量、构成比及用药频度(DDDs)。结果:从各类药物销售金额的构成比来看,抗病毒类药所占比重最大,每年在75%以上,保肝降酶类药次之;从单品种药来看,销售金额以抗病毒药恩替卡韦和阿德福韦酯居前2位;从DDDs排序来看,列前3位的分别为阿德福韦酯、葫芦素和恩替卡韦。结论:该院门诊治疗病毒性肝炎采用以抗病毒药为主,免疫调节、保肝降酶为辅的治疗方案。
OBJECTIVE： To investigate the consumption situation of anti-virus hepatitis drugs in clinic and make evaluation. METHODS： The utilization of anti-virus hepatitis drugs in outpatient department of a hospital from 2007 to 2010 was analyzed statistically in respect of consumption sum, main variety, amount, constituent ratio and DDDs. RESULTS：Anti-virus drugs took the biggest proportion in term of constituent ratio of consumption sum, at least 75% every year, followed by drugs for protecting liver and lowering transaminase. Adefovir dipivoxil and entecavir got the 1st and 2nd place in respect of consumption sum. Adefovir dipivoxil, cucurbitacin and entecavir got the front positions in the DDDs order. CONCLUSION：At present, the virus hepatitis therapy mainly bases on anti-virus drugs, with assistance of immune-modulating drugs and protecting liver and lowering transaminase.
出处
《中国药房》
CAS
CSCD
北大核心
2011年第42期3952-3954,共3页
China Pharmacy
